摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-aminoethoxyamine dihydrochloride | 37866-45-8

中文名称
——
中文别名
——
英文名称
2-aminoethoxyamine dihydrochloride
英文别名
2-(aminooxy)ethanamine dihydrochloride;O-(2-aminoethyl)-hydroxylamine dihydrochloride;2-(Aminooxy)ethanamine hydrochloride;O-(2-aminoethyl)hydroxylamine;hydrochloride
2-aminoethoxyamine dihydrochloride化学式
CAS
37866-45-8
化学式
C2H8N2O*2ClH
mdl
——
分子量
149.02
InChiKey
FZDKEAZDPFKHPJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    205-207°
  • 溶解度:
    可溶于DMSO(少许)、甲醇(少许)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.74
  • 重原子数:
    6
  • 可旋转键数:
    2
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    61.3
  • 氢给体数:
    3
  • 氢受体数:
    3

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 安全说明:
    S24,S37,S61
  • 危险类别码:
    R52/53,R43
  • 海关编码:
    2922199090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335

SDS

SDS:9764f3a9fd18416b33863bff5fb0fe1b
查看

反应信息

点击查看最新优质反应信息

文献信息

  • Derivatives of thioformamide
    申请人:Rhone-Poulenc Sante
    公开号:US05151436A1
    公开(公告)日:1992-09-29
    Therapeutically useful thioformamide derivatives of the formula: ##STR1## wherein R represents alkyl, Het represents pyrid-3-yl, isoquinolin-4-yl, tetrahydroquinolin-3-yl, quinolin-3-yl, pyridazin-4-yl, pyrimid-5-yl, thiazol-5-yl, thieno[2,3-b]-pyridin-5-yl, pyrazin-2-yl, indol-3-yl and thieno[3,2-b]-pyridin-6-yl, Y represents ethylene, methylene or a valency bond, and X represents carbonyl, hydroxymethylene, >C.dbd.NOR.sup.1, >C.dbd.NN(R.sup.1).sub.2 or >C.dbd.NN(R.sup.1)CON(R.sup.1).sub.2 in which R.sup.1 represents hydrogen or optionally substituted alkyl, benzyl, phenethyl, 1-naphthylmethyl, 2-naphthylmethyl or pyrid-3-ylmethyl, or two R.sup.1 substituents on the same nitrogen atom may together form an optionally substituted alkylene radical chain and salts thereof, processes for their preparation and compositions containing them are described.
    公式为:##STR1## 其中R代表烷基,Het代表吡啶-3-基,异喹啉-4-基,四氢喹啉-3-基,喹啉-3-基,吡啶并嗪-4-基,嘧啶-5-基,噻唑-5-基,噻吩[2,3-b]-吡啶-5-基,吡嗪-2-基,吲哚-3-基和噻吩[3,2-b]-吡啶-6-基,Y代表乙烯,亚甲基或一个价键,X代表羰基,羟甲基,>C.dbd.NOR.sup.1,>C.dbd.NN(R.sup.1).sub.2或>C.dbd.NN(R.sup.1)CON(R.sup.1).sub.2,其中R.sup.1代表氢或可选择地取代的烷基,苄基,苯乙基,1-萘甲基,2-萘甲基或吡啶-3-甲基,或同一氮原子上的两个R.sup.1取代基可能共同形成一个可选择地取代的烷基链,以及它们的盐,描述了其制备方法和含有它们的组合物。
  • Novel 7-Oxyiminomethyl Derivatives of Camptothecin with Potent in Vitro and in Vivo Antitumor Activity
    作者:Sabrina Dallavalle、Anna Ferrari、Barbara Biasotti、Lucio Merlini、Sergio Penco、Grazia Gallo、Mauro Marzi、Maria Ornella Tinti、Roberta Martinelli、Claudio Pisano、Paolo Carminati、Nives Carenini、Giovanni Beretta、Paola Perego、Michelandrea De Cesare、Graziella Pratesi、Franco Zunino
    DOI:10.1021/jm0108092
    日期:2001.9.1
    In an attempt to synthesize potential anticancer agents acting by inhibition of topoisomerase I (Topo I) a new series of oxyiminomethyl derivatives in position 7 of camptothecin (CPT) was prepared. The synthesis relied on the condensation of 20S-CPT-7-aldehyde or 20S-CPT-7-ketones with alkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl O-substituted hydroxylamines. The compounds were tested for
    为了合成可能通过抑制拓扑异构酶I(Topo I)起作用的潜在抗癌药,制备了喜树碱(CPT)7位上的一系列新的氧亚氨基甲基衍生物。合成依赖于20S-CPT-7-醛或20S-CPT-7-酮与烷基,芳基,杂芳基,芳基烷基和杂芳基烷基O取代的羟胺的缩合。测试了这些化合物在体外对H460非小肺癌细胞系的细胞毒性活性,该活性针对0.01-0.3 microM范围内的37种化合物中的24种。QSAR分析表明,亲脂性是与细胞毒性相关的主要参数。对DNA-Topo I-药物可裂解复合物的研究表明,细胞毒性与Topo I抑制之间存在大致平行的关系。NaCl介导的三元复合物破坏后DNA裂解的持续性表明,对于最有效的化合物(例如15),细胞毒性至少部分与复合物的稳定有关,这也得到了DNA-的持续性的支持。药物处理细胞中的酶复合物。使用人肺肿瘤异种移植模型,与托泊替康直接比较,评估了最有效类似物(15)的体内抗肿瘤功效。在最佳剂量(2-3
  • AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS
    申请人:Cerri Alberto
    公开号:US20110053902A1
    公开(公告)日:2011-03-03
    Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na + , K + -ATPase. Said compounds are used for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.
    化合物的化学式(I),其中:所述基团如描述中所定义,可用于制备用于治疗心血管疾病,特别是心力衰竭和高血压的药物。这些化合物是Na+,K+-ATP酶活性的抑制剂。所述化合物用于制备一种药物,用于治疗由内源性欧巴因的高血压效应引起的疾病,例如在常染色体显性多囊肾病(ADPKD)中肾功能衰竭进展、妊娠期高血压和蛋白尿以及具有adducin多态性的患者中的肾功能衰竭进展。
  • NOVEL ANTIBACTERIAL COMPOUNDS, METHODS OF MAKING THEM, AND USES THEREOF
    申请人:CARR GRANT J.
    公开号:US20120010163A1
    公开(公告)日:2012-01-12
    The present invention relates to novel therapeutics with antibacterial activity, processes for their preparation, and pharmaceutical, veterinary and nutritional compositions containing them as active ingredients. The present invention also relates to uses of the novel therapeutics, for example, as medicants or food additives in the treatment of bacterial infections or to aid body mass gain in a subject.
    本发明涉及具有抗菌活性的新型治疗药物,其制备过程以及包含它们作为活性成分的药用、兽医和营养组合物。本发明还涉及新型治疗药物的用途,例如,作为药物或食品添加剂用于治疗细菌感染或帮助受试者增加体重。
  • Structure-Based Design and Synthesis of Novel Potent Na<sup>+</sup>,K<sup>+</sup>-ATPase Inhibitors Derived from a 5α,14α-Androstane Scaffold as Positive Inotropic Compounds
    作者:Sergio De Munari、Alberto Cerri、Mauro Gobbini、Nicoletta Almirante、Leonardo Banfi、Giulio Carzana、Patrizia Ferrari、Giuseppe Marazzi、Rosella Micheletti、Antonio Schiavone、Simona Sputore、Marco Torri、Maria Pia Zappavigna、Piero Melloni
    DOI:10.1021/jm030830y
    日期:2003.8.1
    The design, synthesis, and biological properties of novel inhibitors of the Na(+),K(+)-ATPase as potential positive inotropic compounds are reported. Following our model of superposition between cassaine and digitoxigenin, digitalis-like activity has been elicited from a non-digitalis steroidal structure by suitable modifications of the 5alpha,14alpha-androstane skeleton. The strong hydrophobic interaction
    据报道,Na(+),K(+)-ATPase新型抑制剂作为潜在的正性变力性化合物的设计,合成和生物学特性。遵循我们在卡萨因和洋地黄毒苷之间叠加的模型,通过对5alpha,14alpha-androstane骨架进行适当的修饰,从非洋地黄类固醇结构引发了洋地黄样活性。以雄甾烷骨架取反方向,可以有效地获得洋地黄或酪assa碱多环核的强疏水相互作用。因此,我们最近引入的有效药效基团的C-6氧化和在C-3位置的引入(在洋地黄骨架的17位),即O-(ω-氨基烷基)肟,导致了一系列的能够抑制Na(+),K(+)-ATPase的取代雄蕊 它们大多数具有低微摩尔水平的IC(50),并在豚鼠中引起正性肌力作用。在该系列中,当两种化合物时,雄甾烷-3,6,17-三酮(E,Z)-3-(2-氨基乙基)肟(22b,PST 2744)产生强烈的正性肌力作用,而心律失常性低于地高辛。以等熵剂量进行比较。
查看更多